DT120

DT120 (formerly MM120, lysergide D-tartrate, orally disintegrating tablet) is Definium Therapeutics' lead Phase 3 asset for Major Depressive Disorder, evaluated in the Emerge trial (NCT07592689) with change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) at Week 6 as the primary endpoint. The 165-patient enrollment is small for a Phase 3 MDD program and only makes statistical sense given the large effect sizes observed in the Phase 2b GAD program for the same compound. Definium Therapeutics (NASDAQ: DFTX) is the January 2026 rebrand of Mind Medicine (formerly MNMD), and DT120 carries an FDA Breakthrough Therapy Designation (BTD, a designation that expedites development and review for serious conditions) in generalized anxiety disorder, peer-reviewed Phase 2b efficacy data in JAMA, and three Phase 3 readouts expected across 2026 (Voyage and Panorama in GAD, Emerge in MDD). [1][2][4][5][6][9]

DT120 is in Phase 3 for MDD via the Emerge trial (NCT07592689), recruiting as of June 2026, with topline readout expected in the second half of 2026. [1][6] The sponsor, Definium Therapeutics, Inc. (NASDAQ: DFTX), is the rebranded Mind Medicine (MindMed); the corporate name change took effect January 9, 2026 and shares began trading under DFTX on January 13, 2026 (previously MNMD). [6][7] DT120 is the same molecular entity as the company's prior MM120 program: lysergide D-tartrate (LSD) formulated as an orally disintegrating tablet. DT120/MM120 holds an FDA Breakthrough Therapy Designation (BTD) for GAD, granted March 7, 2024 based on the MMED008 Phase 2b trial. [9] BTD applies to the GAD indication, not formally to MDD, but signals FDA engagement with the compound and class. Across the late-stage pipeline, Voyage (NCT06741203, MM120/DT120 Phase 3 for GAD) reads out first half of 2026, Panorama (Phase 3 GAD, international) reads out second half of 2026, and Emerge (Phase 3 MDD) reads out second half of 2026. [6] The sponsor files with the SEC under DFTX, most recent 10-K dated February 26, 2026 and 10-Q dated May 7, 2026. [4][5] A single positive Phase 3 in MDD is rarely sufficient for approval absent a Special Protocol Assessment (SPA, a written FDA agreement that locks in trial design as adequate for approval); the more likely path is reliance on Emerge plus the GAD Phase 3 program plus the Phase 2b dataset.

DT120 is lysergide D-tartrate (LSD), a serotonin 5-HT2A receptor agonist of the classic-psychedelic class, formulated as an orally disintegrating tablet (ODT) for in-clinic monitored dosing. [2][3][6] The same receptor family is hit by psilocybin and other classic serotonergic psychedelics. The therapeutic hypothesis for affective disorders is rapid-onset, dose-dependent serotonergic neuroplasticity producing durable symptom reduction from a single dose, an effect mechanism that contrasts with daily monoamine reuptake inhibitors (SSRIs/SNRIs) and is most directly analogous to single-dose ketamine and esketamine via NMDA antagonism. The MDD rationale is extrapolation from the GAD Phase 2b dataset (large effect size, single dose, 12-week durability) plus broader Phase 2 psilocybin data in TRD and MDD. Independent risks to the mechanistic thesis remain: classical 5-HT2A agonism carries known perceptual effects requiring in-clinic dosing infrastructure, and durability beyond single-dose Phase 2 windows in MDD specifically is not yet shown for DT120.

NCT07592689 is the Emerge Phase 3 study, sponsored by Definium Therapeutics US, Inc. [1][6] The primary endpoint is change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) at Week 6. MADRS is the standard clinician-rated depression severity scale, ten items scored 0 to 60, with higher scores meaning more severe depression. Six-week MADRS change is a conventional efficacy timepoint in MDD registration trials, used in the approval packages for vortioxetine and vilazodone among others. (Esketamine's TRANSFORM Phase 3 program used a Day 28 / 4-week double-blind induction endpoint, reflecting its acute-use paradigm, and is not a Week 6 comparator.) The enrollment target of 165 is small for a Phase 3 MDD program. Modern SSRI/SNRI Phase 3 studies typically enrolled 300 to 500 per study, and esketamine Phase 3 trials ran 200 to 300 per arm. A 165-patient program only makes statistical sense if the expected drug-versus-placebo separation is unusually large, which is plausible given that MM120 100 µg in the JAMA-published Phase 2b GAD trial produced a 65% clinical response and 48% clinical remission rate at Week 12 from a single dose. [10] The single-dose, in-clinic, ODT delivery model also collapses adherence variance compared with daily oral antidepressants. The comparator structure (placebo, active comparator, or dose-ranging) is not detailed in the public registry record, so the statistical strength of the design cannot be fully evaluated from outside the company. [1]

The model gives this drug a 15% chance of eventual approval. It starts from a historical baseline of about 51% for Phase 3 drugs in this area, then adjusts that figure using ten facts about the trial and sponsor. The number is nudged up by having more secondary endpoints than usual, and nudged down by the sponsor's weak approval record, limited earlier-phase results, and heavier-than-usual blinding. The remaining facts fall close to average for this stage and leave the estimate largely unchanged.

Efficacy risk dominates. MDD Phase 3 trials fail at high rates primarily because of placebo response, which routinely runs 6 to 10 points on MADRS and frequently swallows the active drug's effect. [8] A 165-patient trial with a Week 6 readout has limited statistical cushion if drug-placebo separation is modest. Safety risk centers on known serotonergic-psychedelic class signals: acute perceptual effects requiring monitored in-clinic dosing, transient blood pressure elevation, hallucinogen persisting perception disorder (HPPD, a rare condition where visual disturbances continue after the drug has cleared), and theoretical cardiac valve risk from chronic 5-HT2B agonism (the 5-HT2B receptor sits on heart valve tissue and chronic stimulation has historically been linked to valvulopathy with serotonergic drugs like fenfluramine); single-dose DT120 mitigates the chronic-exposure version of that risk. Execution risk: Definium is transitioning from a single late-stage program company to running three Phase 3 trials in parallel, which is operationally hard for a company of its size. Regulatory risk: a single adequate and well-controlled Phase 3 trial is rarely sufficient for MDD approval, and the FDA typically requires two positive Phase 3 trials or a Special Protocol Assessment (SPA, a binding FDA agreement on trial design and analysis plan) that locks in a single-trial path; New Drug Application (NDA, the marketing application submitted to the FDA) success likely requires the broader Voyage/Panorama package as supportive evidence. Commercial risk: MDD is crowded with cheap generic SSRIs/SNRIs, Spravato (esketamine, ~$1.1B 2024 net trade sales per Johnson & Johnson 2024 10-K [11]), Auvelity (dextromethorphan/bupropion, ~$286M 2024 net product revenue per Axsome 2024 10-K [12]), and active Phase 3 programs from Compass Pathways (COMP360 psilocybin, two positive Phase 3 readouts in TRD with COMP005 and COMP006, 26-week durability data due H2 2026, NDA filing planned Q4 2026 [13]) and Beckley Psytech (BPL-003, intranasal mebufotenin/5-MeO-DMT benzoate, Phase 2b complete, Phase 3 in development [14]). In-clinic dosing infrastructure (REMS-equivalent monitoring) will also be a payer-access friction point similar to Spravato.

Promoted to active watch. With the MindMed → Definium rebrand and corrected mechanism (LSD-tartrate ODT, 5-HT2A agonist), this is a tracked psychedelic-class Phase 3 with peer-reviewed Phase 2b data, BTD on the parent compound, and three readouts inside a 12-month window. Key catalysts: Voyage Phase 3 GAD topline (1H 2026) is the single most informative event, since positive Voyage de-risks the molecule and reframes Emerge from a binary bet to a confirmatory readthrough; Panorama (2H 2026) and Emerge (2H 2026) follow. Watch for Definium's next 10-Q for cash runway disclosure (running three Phase 3 trials is capital-intensive and dilution risk is real), management commentary at JPMorgan Healthcare Conference (January 2027) and American Society of Clinical Psychopharmacology (May 2027), and any 8-K filings disclosing FDA AdCom (Advisory Committee, an FDA expert panel that votes on approval recommendations) scheduling or Type B meeting outcomes (Type B is the FDA pre-NDA meeting category covering pre-IND, end-of-Phase-2, and pre-NDA discussions). The setup is asymmetric in both directions: a clean Voyage readout plus a positive Emerge readout in MDD opens a multi-indication psychedelic franchise; a Voyage miss collapses the thesis before Emerge reads out. Decision-grade information arrives with Voyage. Until then, treat DT120/Emerge as a moderate-confidence Phase 3 asset with parent-compound efficacy support, real placebo-response risk in MDD, and meaningful catalyst density across H2 2026. [1][6][9][10]